Everest Clinical Research has acquired August Research with an eye on the European clinical trials market.
The deal – financial terms of which were not disclosed – will provide Everest with operations in 14 countries in Western and Eastern Europe. It will also add August’s trial services and pharmacovigilance units to Everest’s network.
Malcolm Little from Arlington Capital Partners, Everest’s private equity owner, cited territorial expansion as the motivation for the takeover.
“The acquisition of August is highly strategic for Everest as it further expands our global service offering and establishes a beachhead in one of the largest clinical trial markets in the world. With the addition of several European offices to complement Everest’s existing presence in North America and Asia, Everest further engrains itself as a truly global CRO.”
August founders Dana Leff Niedzielska and Lukasz Niedzielski will continue as key executive leaders with the business post-transaction, which was highlighted as a positive by Everest COO, Jin Dai.
“Dana, Lukasz and their tenured leadership team have built a strong client and people-focused culture at August that aligns extremely well with the broader Everest organization. Their expertise in and dedication to the field of clinical research are truly impressive.
“We look forward to working together to introduce August’s leading European clinical operations capabilities to our US customer base and build out a broader and quality-focused biometrics and data management practice in Europe.”
Arlington made a majority investment in Everest in November 2020. At the time Everest said Arlington will provide significant strategic and financial support to grow the Everest business and further strengthen its platform for accelerated growth.
Since then the private equity firm has overseen a number of expansions. Last year, for example, Everest bought Brightech International, CRO that specializes in complex, value-add biostatistics, programming and clinical data management.